GleamWall
中文EN

LRMR Larimar Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1374690 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-18.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-129.8%
ROA-95.2%
ROIC (approx.)-348.7%
Asset turnover—

Leverage & solvency

Liabilities / assets27.8%
Debt / equity0.00x
Current ratio3.82x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.01x
Accruals ratio1.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$154.22M$73.28M
SG&A expense$18.27M$17.61M
Operating income-$172.50M-$90.89M
Pretax income-$165.67M-$80.60M
Income tax$0$0
Net income-$165.67M-$80.60M
EBITDA-$172.15M-$90.57M
EPS (basic)—-1.32
EPS (diluted)—-1.32
Weighted avg. shares (diluted)—61.26M
Balance sheet
Cash & equivalents$85.41M$33.22M
Short-term investments$51.44M$150.24M
Current assets$142.02M$195.30M
PP&E, net$622,000$881,000
Total assets$145.84M$200.22M
Current liabilities$64.80M$24.36M
Total liabilities$67.76M$28.41M
Shareholders' equity$78.08M$171.81M
Shares outstanding83.09M63.82M
Cash flow statement
Operating cash flow-$113.20M-$70.76M
Capital expenditure$91,000$515,000
Free cash flow-$113.29M-$71.28M
Investing cash flow$100.31M-$85.39M
Financing cash flow$65.09M$161.88M
Depreciation & amortization$350,000$318,000
Stock-based compensation$7.00M$8.80M

Free plan shows the latest 2 periods; Pro shows all 14 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.